Literature DB >> 2300545

The effects of urine pH modification on the pharmacokinetics and pharmacodynamics of phenylpropanolamine.

C L Zimmerman1, M B O'Connell, I Soria.   

Abstract

To determine whether urinary alkalinization had an effect on the plasma pharmacokinetics and pharmacodynamics of phenylpropanolamine, a double-blind crossover study was conducted in four healthy, normotensive male volunteers. The subjects received 25 mg immediate-release phenylpropanolamine and either placebo or sodium bicarbonate in a balanced randomized order. The bicarbonate treatment consisted of 6 g sodium bicarbonate 30 min prior to the phenylpropanolamine and then 3 g sodium bicarbonate every 4 hr for the next 16 hr. During the control treatment, phenylpropanolamine and a placebo for bicarbonate (lactose) were given on the same schedule. Blood and urine samples were collected over 24 hr and analyzed by HPLC. A supine blood pressure and pulse were obtained before each blood sample. The bicarbonate treatment significantly increased the urine pH throughout the study period and decreased phenylpropanolamine renal clearance by 33.5%. The apparent total-body clearance was also decreased by 31.5% and resulted in higher postabsorptive plasma phenylpropanolamine concentrations in each subject as compared to the control treatment. Both systolic and diastolic blood pressures changed significantly from baseline in both treatments. The bicarbonate treatment was accompanied by significantly higher diastolic blood pressures than in the control treatment, but there was no effect on systolic blood pressures. Generally, when the blood pressure-concentration pairs were plotted chronologically, clockwise hysteresis curves resulted. Heart rates did not change significantly from baseline values for either treatment. In this small group of normotensive healthy male volunteers, urinary alkalinization significantly depressed the renal clearance of phenylpropanolamine, producing higher postabsorptive phenylpropanolamine plasma concentrations and a small but significant increase in the diastolic blood pressure.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2300545     DOI: 10.1023/a:1015852012968

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  15 in total

1.  RHYTHMIC URINARY EXCRETION OF AMPHETAMINE IN MAN.

Authors:  A H BECKETT; M ROWLAND
Journal:  Nature       Date:  1964-12-19       Impact factor: 49.962

2.  Circadian rhythm of urinary pH in man with and without chronic antacid administration.

Authors:  J W Ayres; D J Weidler; J MacKichan; J G Wagner
Journal:  Eur J Clin Pharmacol       Date:  1977-12-28       Impact factor: 2.953

3.  Absorption metabolism and excretion of the ephedrines in man. I. The influence of urinary pH and urine volume output.

Authors:  G R Wilkinson; A H Beckett
Journal:  J Pharmacol Exp Ther       Date:  1968-07       Impact factor: 4.030

4.  Extended least squares nonlinear regression: a possible solution to the "choice of weights" problem in analysis of individual pharmacokinetic data.

Authors:  C C Peck; S L Beal; L B Sheiner; A I Nichols
Journal:  J Pharmacokinet Biopharm       Date:  1984-10

Review 5.  Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models.

Authors:  N H Holford; L B Sheiner
Journal:  Clin Pharmacokinet       Date:  1981 Nov-Dec       Impact factor: 6.447

6.  Effect of an anti-asthmatic compound on blood pressure of hypertensive asthmatic patients.

Authors:  D L Unger; L Unger; D E Temple
Journal:  Ann Allergy       Date:  1967-05

7.  "Salt-sensitive" essential hypertension in men. Is the sodium ion alone important?

Authors:  T W Kurtz; H A Al-Bander; R C Morris
Journal:  N Engl J Med       Date:  1987-10-22       Impact factor: 91.245

8.  Phenylpropanolamine: effects on subjective and cardiovascular variables at recommended over-the-counter dose levels.

Authors:  I Liebson; G Bigelow; R R Griffiths; F R Funderburk
Journal:  J Clin Pharmacol       Date:  1987-09       Impact factor: 3.126

9.  Comparison of effects of two dosage regimens of phenylpropanolamine on blood pressure and plasma levels in normal subjects under steady-state conditions.

Authors:  M B Saltzman; M M Dolan; N Doyne
Journal:  Drug Intell Clin Pharm       Date:  1983-10

10.  Individual variability in the blood pressure response to intravenous phenylpropanolamine: a pharmacokinetic and pharmacodynamic investigation.

Authors:  M B O'Connell; P R Pentel; C L Zimmerman
Journal:  Clin Pharmacol Ther       Date:  1989-03       Impact factor: 6.875

View more
  2 in total

1.  Elimination of ephedrines in urine following multiple dosing: the consequences for athletes, in relation to doping control.

Authors:  Neil Chester; David R Mottram; Thomas Reilly; Mark Powell
Journal:  Br J Clin Pharmacol       Date:  2004-01       Impact factor: 4.335

2.  Use of pharmacologic data and computer simulations to design an efficacy trial of intravesical mitomycin C therapy for superficial bladder cancer.

Authors:  M G Wientjes; R A Badalament; J L Au
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.